The results of this work, published in the journal Antimicrobial Agents and Chemotherapy , and part of Sergio Ortega del Campo’s Doctoral Thesis, recently defended within the Molecular and Cellular Biology Doctoral Program of the UMA, pave the way for the development of more effective therapies against emerging viruses, as well as combating new, more resistant variants of coronavirus.
Dual action
Professor at the Department of Cell Biology, Genetics and Physiology Ana Grande, one of the main authors of this research, explains that, on the one hand, they designed small peptides –protein fragments– capable of blocking key viral proteins involved in the replication of its genetic material and the immune evasion and, on the other hand, they used a compound (5-fluorouracil) that introduces errors during viral genome replication.
“Independently, both mechanisms reduce the virus’s ability to infect. However, when combined, they produce a much more powerful synergistic effect: while the peptides hinder replication, the compound increases the accumulation of mutations that leads the virus to a situation of ‘error catastrophe’ achieving near-complete loss of infectivity,” says the UMA scientist.
According to Grande, this study also demonstrates that this combined treatment not only reduces the viral load but also strongly alters its genetic diversity, “destabilizing the viral population and facilitating its extinction”. This dual action causes, therefore, a synergistic effect: the virus not only replicates less efficiently but also accumulates mutations to the point of non-viability of the virus.
“Moreover, since the viral proteins targeted by peptides are highly conserved among different coronaviruses, this strategy could have wider applications in the development of broad-spectrum antivirals,” she says.
Multidisciplinary work: from computational design to experimental validation
‘Synergistic antiviral effects of structure-guided peptides and a mutagenic base analog on SARS-CoV-2 replication’ is the result of a multidisciplinary work in which, together with the UMA, researchers from IBIMA Platforma BIONAND, Hospital Universitario Virgen de la Victoria of Malaga, IDIBE-Universidad Miguel Hernández, from the Severo Ochoa Molecular Biology Center (CSIC-UAM), Universidad Autónoma de Madrid and Fundación Jiménez Díaz have all participated, allowing the problem to be approached from different perspectives, from computational design to experimental validation.
Although this is a laboratory study, specifically conducted in cell cultures, its developers, who continue to pursue this line of R&D, have applied for a patent to protect this therapeutic approach, with the aim of facilitating its possible transfer and future development.
This study was initiated thanks to a project funded by the Government of Andalusia within the scope of the Research Projects on SARS-CoV-2 and COVID-19 disease co-financed with ERDF funds, which has allowed progress in the development of new therapeutic approaches against the virus.
Bibliography:
Ortega Del Campo S, Fernández Ballester GJ, Blanes Mira C, Guirado Osorio V, Díaz Martínez L, de Ávila AI, Soria ME, Martínez-González B, Villena González FJ, Gómez-Maldonado J, Viciana Ramos MI, Clavijo Frutos E, Santos González JL, Bastolla U, Perales C, Domingo E, Viguera E, Fernández Escamilla AM, Grande Pérez A. 0 (2026) Synergistic antiviral effects of structure-guided peptides and a mutagenic base analog on SARS-CoV-2 replication. Antimicrob Agents Chemother 0:e01885-25. https://doi.org/10.1128/aac.01885-25
Experimental study
Cells
Synergistic antiviral effects of structure-guided peptides and a mutagenic base analog on SARS-CoV-2 replication
27-Apr-2026